Microarray-Based Technology Improves Preimplantation Genetic Diagnosis

The microarray-based technology was tested and developed for in vitro fertilization (IVF) and has multiple advantages when applied to preimplantation genetic diagnosis (PGD).

The test has the ability to screen all chromosomes whereas conventional techniques typically selectively screen approximately half. It can be performed successfully with the genetic material of a single cell sample during the standard timeline of IVF with a one-day turnaround time. It works rapidly and efficiently for preimplantation use with in vitro fertilization.

Empire Genomics (Buffalo, NY, USA) developed a technology called array-based comparative genomic hybridization (aCGH) that determines gains or losses of genetic material to streamline screening for chromosomal defects such as Down's syndrome. DNA microarray technology places DNA representing genes and chromosomes on a slide for comparison with a normal set, and collaboration between Reprogenetics (San Francisco, CA, USA) and Empire Genomics has resulted in the successful application of this technology to preimplantation genetic screening.

"We are convinced this new technology will enable us to improve screening for genetic defects as well as improve the pregnancy outcome for patients undergoing IVF by reducing spontaneous abortions and genetically affected conceptions,” said Santiago Munne, Ph.D., Reprogenetics director. "Currently, PGD requires highly skilled and experienced embryologists to process the cells for the current technology. This new technology simplifies this step making PGD more accessible to IVF centers and their patients.”

The data were presented jointly by Empire Genomics and Reprogenetics at the 63rd annual meeting of the American Society for Reproductive Medicine (ASRM; Birmingham, AL, USA) in Washington, DC (USA) on Wednesday, October 17, 2007.


Related Links:
Empire Genomics
Reprogenetics
American Society for Reproductive Medicine